Renaissance Technologies
ARDS

Renaissance Technologies’s Aridis Pharmaceuticals Inc. Common Stock ARDS Stock Holding History

Renaissance Technologies’s Portfolio ARDS Stock Details ARDS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-10,804
Closed -$12K – 4528
2022
Q2 		$12K Buy
+10,804
New +$13.4K ﹤0.01% 4156

Other funds holding ARDS

Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RAM
Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
EWA
EP Wealth Advisors Torrance, California $20.3B AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies's ARDS Position: Q3 2022 in Review

Renaissance Technologies sold out of Aridis Pharmaceuticals Inc. Common Stock (ARDS) in Q3 2022, closing a stake of 10,804 shares — an estimated $12K sold.

Renaissance Technologies first reported a position in ARDS in Q2 2022 and held it in 1 quarter. The position peaked at $12K in Q2 2022. 16 funds tracked by Wall St. Rank hold ARDS as of Q3 2022.

  • Renaissance Technologies reported no remaining Aridis Pharmaceuticals Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • Renaissance Technologies sold 10,804 Aridis Pharmaceuticals Inc. Common Stock shares in Q3 2022, an estimated $12K.
  • Renaissance Technologies first reported a position in Aridis Pharmaceuticals Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • Renaissance Technologies's Aridis Pharmaceuticals Inc. Common Stock position peaked at $12K in Q2 2022.
  • 16 funds tracked by Wall St. Rank held Aridis Pharmaceuticals Inc. Common Stock as of Q3 2022.

Based on Renaissance Technologies's 13F filing for Q3 2022, filed 14 Nov 2022.